Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA Approves 1st Non-Opioid Pain Medicine in 20 Years
FDA approves new type of non-opioid pain medication, 1st of its kind in more than 20 years
The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.
FDA approves Vertex non-opioid pain drug
The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why it matters: Millions of Americans with acute and chronic pain are prescribed opioids,
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.
2d
Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...
clinicaladvisor.com
6d
Astronauts Experience Acute and Chronic Pain During and After Spaceflight
Researchers assessed physiologic changes of the spine as well as the frequency of low back pain among astronauts during and after spaceflight.
3d
FDA approves opiate-alternative acute pain management drug, local experts share their thoughts
On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...
clinicalpainadvisor.com
3d
Chronic Postoperative Pain Remains Common Despite Multimodal Analgesia
Acute and chronic postoperative pain and functional disability persisted among patients who underwent posterior spinal fusion despite multimodal analgesic management.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback